Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | What role will erdafitinib play in treating metastatic urothelial carcinoma?

Arlene Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the future of erdafitinib in the treatment landscape for metastatic urothelial carcinoma. Frontline treatments for metastatic urothelial carcinoma remain an unmet need, where approximately half of patients are not eligible for the standard of care. Findings from the Phase III THOR trial (NCT03390504) confirmed the promising benefits of erdafitinib, and additional studies will compare the drug to existing therapies such as gemcitabine with carboplatin, or enfortumab vedotin plus pembrolizumab. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.